BI 695501 regulatory update

Boehringer Ingelheim said FDA and EMA accepted for review regulatory applications for BI 695501, a biosimilar of Humira adalimumab from AbbVie Inc. (NASDAQ:ABBV, Chicago, Ill.). Last October, Boehring...